# Study to Investigate the Pharmacokinetics, Safety and Tolerability of Odalasvir and AL-335 in Healthy Japanese Participants

> **NCT02821858** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Odalasvir (ODV)
- **DRUG:** AL-335
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02821858
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-14
- **Primary completion:** 2016-09-09
- **Final completion:** 2016-09-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02821858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02821858, "Study to Investigate the Pharmacokinetics, Safety and Tolerability of Odalasvir and AL-335 in Healthy Japanese Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02821858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*